In 2014, PATH conducted interviews with stakeholders in Senegal and Uganda to assess receptivity to self-injection of the contraceptive, subcutaneous DMPA (DMPA-SC, brand name Sayana Press) as well as the evidence requirements and processes necessary to chart a course for adoption, introduction, and scale-up of self-injection as a service-delivery practice in the two countries. For more information, email FPoptions@path.org or visit www.path.org/dmpa-sc.